P1.14-61 EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR+ NSCLC Patients with BIM Deletions

Autor:	C. Martin, Rosa Rosell, Pilar Archila, Luisa Ricaurte, V. Cordeiro De Lima, Luis Mas, Carlos Vargas, Feliciano Barrón, Andrés Felipe Cardona, C. Sotelo, L. Rojas, Jorge Otero, Luis Corrales, Hernán Carranza, Alejandro Ruiz-Patiño, D. Mayorga, J. Ávila, Helano C. Freitas, Z.L. Zatarain Barrón, Oscar Arrieta, July Rodriguez
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine Oncology Bevacizumab business.industry medicine Cancer research business medicine.drug EGFR inhibitors
Zdroj:	Journal of Thoracic Oncology. 14:S579
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2019.08.1212
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ce3b70bee09311ace085d68c94c7c9e7 https://doi.org/10.1016/j.jtho.2019.08.1212 Zobrazit plný text záznamu